Home > Neurology > AAN 2018 > Letter from the Editor

Letter from the Editor

Prof. Nikolaos Grigoriadis, Aristotle University of Thessaloniki, Greece
AAN 2018
Dear Reader, Another successful AAN meeting took place this year in Los Angeles, 21-27 April 2018. A number of studies had  been announced in a broad spectrum of neurological  disorders. Many studies provided updates with regard to risk-factor identification, innovative approaches in treatment, real-world data, and new clinical trials with known or new innovative compounds. Early intervention with BACE1 inhibitors, retinal changes in preclinical Alzheimer’s disease and immunotherapy against amyloid-β were among the dementia-related updates. In epilepsy, transdermal cannabinoid gel usage, some updates in paediatric epilepsy and the effect of different diets in the disease are worth mentioning. The increasing interest in the use of monoclonal antibodies in the treatment of migraine was evident among the various studies presented. Some progress in movement disorders were presented, namely in new therapeutic interventions either for Parkinson’s or Huntington’s disease. Importa...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on